371
8
31
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16161 |
Mutant IDH1 inhibitor
|
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
Mutant IDH1 inhibitor 是一种突变型IDH1 R132H 的抑制剂,IC50<72 nM。 | |||
T2705 |
Mutant EGFR inhibitor
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Mutant EGFR inhibitor 是选择性EGFR 突变体抑制剂,可抑制EGFRL858R、EGFRExon 19 deletion 和EGFRT790M。 | |||
T12128 |
Mutant IDH1-IN-2
|
Isocitrate Dehydrogenase (IDH) | Metabolism |
Mutant IDH1-IN-2是突变型异柠檬酸脱氢酶蛋白抑制剂, 在荧光生物化学检测中IC50为16.6 nM,LS-MS 生物化学检测中IC50为<22 nM,。 | |||
T2043 |
Mutant IDH1-IN-1
IDH1-IN-1 |
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
Mutant IDH1-IN-1 是 IDH1突变体的选择性抑制剂,能够作用于突变体 IDH1 R132C/R132C (IC50:4 nM) ,IDH1 R132H/R132H (IC50:42 nM) ,IDH1 R132H/WT (IC50:80 nM) 和野生型 IDH1 (IC50:143 nM)。 | |||
T39716 |
Mutant IDH1-IN-6
Mutant IDH1-IN-6 |
Others | Others |
Mutant IDH1-IN-6 is an orally active compound that effectively inhibits mutant isocitrate dehydrogenase (IDH) enzymes. It demonstrates potency and selectivity, with IC50 values of 6.27, 3.71, 36.9, and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q, and IDH2 R172K mutants, respectively. Notably, Mutant IDH1-IN-6 exhibits lower activity in inhibiting wild-type IDH enzymes. | |||
T40272 |
KRAS mutant protein inhibitor 1
|
Others | Others |
KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer. | |||
T12129 | Mutant IDH1-IN-4 | Others | Others |
Mutant IDH1-IN-4 is an mutant Isocitrate dehydrogenase 1 (IDH 1) inhibitor. | |||
T11164 |
EGFR mutant-IN-1
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR mutant- in-1, A 5-methylpyrimidopyridone derivative are effective selective EGFRL858R/T790M/C797S mutant inhibitors with IC50 of 27.5 nM, which significantly weakened EGFRWT effect. | |||
T12685 |
RAF mutant-IN-1
|
Others | Others |
RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively). | |||
T77805 |
KRAS G12C mutant protein inhibitor A-1
|
Others | Others |
KRAS G12C mutant protein inhibitor A-1 可用于 Ras 相关研究。 | |||
T64079 |
Mutant p53 modulator-1
|
Others | Others |
Mutant p53 modulator-1 是一种突变型 p53 调节剂。Mutant p53 modulator-1 能够阻碍含有 p53 突变的癌症的进展。 | |||
T9521 |
CHR-6494 TFA
|
Others | Others |
CHR 6494 TFA 是一种选择性 haspin 抑制剂,IC50值为 2 nM,可抑制组蛋白 H3T3 的磷酸化。它诱导黑色素瘤、乳腺癌等肿瘤细胞凋亡,可研究癌症。 | |||
T8485 |
THIQ
|
Melanocortin Receptor | GPCR/G Protein; Neuroscience |
THIQ 是一种选择性黑皮质素 4 受体 (MC4R) 激动剂,对 hMC4R 和 rMC4R 的 IC50 分别为 1.2 和 0.6 nM。 | |||
T7414 |
ARS-853
|
Apoptosis; Raf; Ras | Apoptosis; GPCR/G Protein; MAPK |
ARS-853 是一种选择性共价KRAS G12C 抑制剂,IC50为 2.5 μM。它通过与 GDP 结合的癌蛋白结合并阻止激活来抑制突变 KRAS 驱动的信号传导。 | |||
T16384 |
Olutasidenib
FT-2102 |
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
Olutasidenib (FT-2102) 是一种可透过血脑屏障的、具有口服活性的、突变型异柠檬酸脱氢酶(IDH)1的选择性有效抑制剂,对IDH1- R132H 和 IDH1- R132C 的IC50分别为 21.2 nM 和 114 nM,可用于急性髓性白血病或骨髓增生异常综合征的研究。 | |||
T9303 |
MRTX1133
|
Ras | GPCR/G Protein; MAPK |
MRTX1133 是一种 KRAS G12D 抑制剂 (KD=0.2 pM),具有强效性、选择性和非共价性。MRTX1133 对 KRAS G12D 突变的肿瘤具有抑制活性,而对 KRAS 野生型肿瘤无抑制活性。 | |||
T16143 |
MRTX-1257
|
Ras | GPCR/G Protein; MAPK |
MRTX-1257 是选择性的、可口服的不可逆共价KRAS G12C 抑制剂,其在 H358 细胞中测得 KRAS 依赖 ERK 磷酸化的IC50值为 900 pM。 | |||
T9698 |
UC2288
|
Mdm2; p53 | Apoptosis |
UC2288 是新型的、细胞通透性、口服有效的p21衰减试剂,基于索拉非尼的结构合成。在不依赖 于p53的情况下,它可以下调 p21 mRNA 的表达,降低 p21 蛋白水平,对 p21 蛋白的稳定性影响很小。它对VEGFR2 和 Raf 激酶没有抑制作用,即使在 10 μM。 | |||
T13176 |
TNO155
Batoprotafib |
Phosphatase | Metabolism |
TNO155 是具有口服活性野生型SHP2的选择性变构抑制剂 (IC50= 0.011 µM)。它有研究 RTK 依赖性恶性肿瘤(尤其是晚期实体瘤)的潜力。 | |||
T9246 |
JNJ-63576253
|
Androgen Receptor | Endocrinology/Hormones |
JNJ63576253 是具有口服活性的、有效的雄激素受体的完全拮抗剂,在 LNCaP 细胞中对 F877L 突变型 AR 和野生型 AR 的IC50值分别为 37 和 54 nM。它可用于研究去势抵抗性前列腺癌。 | |||
T1921 |
Alpelisib
BYL-719 |
PI3K | PI3K/Akt/mTOR signaling |
Alpelisib (BYL-719) 是一种 PI3Kα 抑制剂 (IC50=5 nM),具有选择性、有效性和口服活性。Alpelisib 以较低活性抑制 PI3Kβ/γ/δ (IC50=250/290/1200 nM)。Alpelisib 具有抗肿瘤活性,对 PIK3CA 突变肿瘤具有靶向性。 | |||
T8369 |
Adagrasib
MRTX849 |
Ras | GPCR/G Protein; MAPK |
Adagrasib (MRTX849) 是一种 KRAS G12C 共价抑制剂,具有口服活性和选择性。Adagrasib 与 KRAS G12C 非活性构象的 GDP 状态结合,抑制 KRAS 及其下游信号的传导。Adagrasib 对 KRAS G12C 突变肿瘤具有抑制活性。 | |||
T8756 |
KRAS inhibitor-9
DUN09716 |
Apoptosis; Ras | Apoptosis; GPCR/G Protein; MAPK |
KRAS inhibitor-9 (DUN09716) 是一种 KRAS 抑制剂,阻止 GTP-KRAS 的形成和 KRAS 下游激活。它以中等的结合亲和力与 KRAS G12D、KRAS G12C 和 KRAS Q61H 蛋白结合,选择性抑制具有 KRAS 突变的 NSC-LC 细胞的增殖。它可导致 G2/M 细胞周期停滞并诱导凋亡。 | |||
T8872 |
(Rac)-JBJ-04-125-02
JBJ-04-125-02 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
(Rac)-JBJ-04-125-02 (JBJ-04-125-02) 是 JBJ-04-125-02 的消旋体,是选择性突变,可口服的 EGFR 变构抑制剂,对EGFRL858R/T790M 的IC50为 0.26 nM。 | |||
T1623 |
Lopinavir
ABT-378,洛匹那韦 |
SARS-CoV; HIV Protease | Microbiology/Virology; Proteases/Proteasome |
Lopinavir (ABT-378) 是一种选择性肽模拟 HIV-1 蛋白酶的高效抑制剂。它通过阻止 HIV-1 的成熟而起作用,从而阻断其感染性。它也是 SARS-CoV 3CLpro 的抑制剂。 | |||
T60076 |
Oritinib
SH-1028 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Oritinib (SH-1028) 是一种 EGFR 抑制剂,对 EGFR (wt)、EGFR (L858R)、EGFR (L861Q)、EGFR (L858R/T790M)、EGFR (d746-750) 的 IC50 分别为 18、0.7、4、0.1、1.4 和 0.89 nM , EGFR (d746-750/T790M), 分别。奥瑞替尼可用于治疗非小细胞肺癌的研究。 | |||
T35343 |
MTI-31
MTI-31,LXI-15029 |
mTOR | PI3K/Akt/mTOR signaling |
MTI-31 (LXI-15029) 是口服有效的,高度选择性的mTORC1和mTORC2抑制剂,对 mTOR 的Kd 为 0.20 nM,IC50为 39 nM。MTI-31可用于乳腺癌的研究。 | |||
T8933 |
JNJ-63576253 free base
TRC253,JNJ-63576253 |
Androgen Receptor | Endocrinology/Hormones |
JNJ-63576253 free base (TRC253) 是具有口服活性的、有效的雄激素受体的完全拮抗剂,在 LNCaP 细胞中对 F877L 突变型 AR 和野生型 AR 的 IC50值分别为 37 和 54 nM。它可用于研究去势抵抗性前列腺癌 (CRPC) 。 | |||
T4459 |
PK11000
|
DNA Alkylator/Crosslinker | DNA Damage/DNA Repair |
PK11000 是一种烷化剂,可通过共价半胱氨酸修饰来稳定野生型和突变型p53的 DNA 结合结构域。 | |||
T9320 |
YK-3-237
B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
Sirtuin | Chromatin/Epigenetic; DNA Damage/DNA Repair |
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) 是 SIRT1 激活剂,靶向突变体 p53。它抑制三阴性乳腺癌细胞的增殖。 | |||
T1952 |
MK-2206 dihydrochloride
MK-2206 2HCl |
Apoptosis; Akt; Autophagy | Apoptosis; Autophagy; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
MK-2206 dihydrochloride (MK-2206 2HCl) 是一种变构 Akt 抑制剂,抑制 Akt1、Akt2 和 Akt3 (IC50=8/12/65 nM),具有口服活性的、高效选择性。MK-2206 dihydrochloride 具有抗肿瘤活性。 | |||
T3184 |
Kevetrin hydrochloride
Thioureidobutyronitrile HCl,thioureido butyronitrile hydrochloride,4-Isothioureidobutyronitrile hydrochloride |
Mdm2; p53 | Apoptosis |
Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride) 是一种小分子,是肿瘤抑制蛋白 p53 的激活剂,具有潜在的抗肿瘤活性。 | |||
T2330 |
Rilpivirine
TMC278,R278474,利匹韦林,DB08864 |
HIV Protease; Reverse Transcriptase | Microbiology/Virology; Proteases/Proteasome |
Rilpivirine (R278474) 是一种二芳基嘧啶衍生物和非核苷逆转录酶抑制剂,具有抗 HIV-1 的抗病毒活性,用于治疗 HIV 感染。 | |||
T9997 |
GLL 398
|
Estrogen Receptor/ERR | Endocrinology/Hormones |
GLL 398 是一种具有口服活性的选择性雌激素受体降解剂,IC50 为 1.14 nM。 GLL 398 在异种移植乳腺癌模型中阻断肿瘤生长。 | |||
T9304 |
(S)-Sunvozertinib
N-[5-[[4-[5-Chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide,DZD9008 |
EGFR; HER | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
(S)-Sunvozertinib (DZD9008) 是 Sunvozertinib 的 S-对映体,能够抑制EGFR 外显子 20 NPH 和 ASV 插入、EGFR L858R/T790M 突变及 Her2 外显子 20 YVMA 插入,也能够抑制BTK。 | |||
T6008 |
CNX-2006
CNX 2006,CNX2006 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CNX-2006 是一种新型的不可逆突变选择性 EGFR 抑制剂,对 EGFRT790M 的IC50值小于 20 nM。 | |||
T15617 |
JNJ-38877618
OMO-1 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
JNJ-38877618 (OMO-1)是一种口服有活性的 Met 激酶选择性抑制剂,其对野生型和突变体的 IC50值分别为2和3 nM。 | |||
T8930 |
CID44216842
KUC103479N-02 |
CDK; Ras | Cell Cycle/Checkpoint; GPCR/G Protein; MAPK |
CID44216842 (KUC103479N-02) 是Cdc42选择性抑制剂。在 GDP 结合测定中,它对 Cdc42 野生型和 Cdc42Q61L 突变型的EC50分别为 0.3 和 0.5 μM。在 GTP 结合测定中,它对 Cdc42 野生型和 Cdc42Q61L 突变型的EC50分别为 1.0 和 1.2 μM。它可用作分子探针。 | |||
T3506 |
Nazartinib
那扎替尼,EGF816,NVS-816 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Nazartinib (EGF816) 是一种共价、不可逆、突变选择性 EGFR 抑制剂,对激活 mt (L858R, ex19del) 和 T790M mt 具有纳摩尔抑制效力,在体外其选择性比野生型 (wt) EGFR 高 60 倍。 | |||
T10375 |
ARS-1323
|
Ras | GPCR/G Protein; MAPK |
ARS-1323 是 ARS-1620 的消旋体。ARS-1323 是突变型K-Ras G12C 的新型抑制剂。 | |||
T6949 |
PLX7904
PB04 |
Raf | MAPK |
PLX7904 (PB04) 是一种有效且选择性的悖论破坏剂 RAF 抑制剂,可抑制突变 BRAF 黑色素瘤细胞中 ERK1/2 的激活。在表达突变体 RAS 的细胞中,对 BRAFV600E 的IC50值约为 5 nM。 | |||
T6954 |
PRIMA-1
2,2-Bis(hydroxymethyl)-3-quinuclidinone,NSC-281668,PRIMA 1 |
Apoptosis; Others; Ferroptosis; Autophagy | Apoptosis; Autophagy; Others |
PRIMA-1 (NSC-281668) 是一种突变型 p53复活剂,可恢复 TP53 突变型甲状腺癌细胞对组蛋白甲基化抑制剂 3-Deazaneplanocin A 的敏感性。 | |||
T10802 |
CHMFL-EGFR-202
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CHMFL-EGFR-202 是一种有效、不可逆的表皮生长因子受体 (EGFR) 突变型激酶抑制剂, 对耐药突变型 EGFR T790M 和 WT EGFR 激酶作用的 IC50 分别为 5.3 nM 和 8.3 nM。 | |||
T23182 |
PPY A
|
Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PPY A 是 T315l 突变体和野生型 Abl 激酶的有效抑制剂(IC50 分别为 9 和 20 nM)。PPY A 还能抑制 Bcr-Abl T315l 突变体或野生型 Bcr-Abl 基因转化细胞的生长。 | |||
T6918 |
Olmutinib
HM61713, BI 1482694,奥莫替尼,BI 1482694,HM61713 |
EGFR; BTK | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Olmutinib (HM61713, BI 1482694) 是可口服的不可逆 EGFR 酪氨酸激酶抑制剂,其与激酶结构域附近的半胱氨酸残基结合,可用于非小细胞肺癌的研究。 | |||
T3024 |
Avitinib
AC0010,艾维替尼 |
EGFR; JAK; BTK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Avitinib (AC0010) 是一种不可逆的、突变体选择性的EGFR 抑制剂,可有效抑制非小细胞肺癌中EGFR T790M 耐药突变。阿比替尼也是一种新型BTK 抑制剂。 | |||
TP1708L |
H-Ala-Ala-Tyr-OH acetate(67131-52-6 free base)
|
Others | Others |
H-Ala-Ala-Tyr-OH acetate(67131-52-6 free base) 可以合成突变肽。 | |||
T16162 |
Mutated EGFR-IN-1
Osimertinib analog,AZD9291中间体1 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Mutated EGFR-IN-1 (Osimertinib analog) 是用于突变 EGFR 抑制剂设计的有用中间体,例如 L858R EGFR、Exon19 缺失激活突变体和 T790M 抗性突变体。 | |||
T7741 |
DS-1001b
|
Dehydrogenase; Isocitrate Dehydrogenase (IDH) | Metabolism |
DS-1001b 是IDH-1(异柠檬酸脱氢酶-1) 突变体抑制剂。 | |||
T1928 |
Anacetrapib
安塞曲匹,MK-0859 |
CETP | Metabolism |
Anacetrapib (MK-0859) 是 CETP 的抑制剂,能够抑制 rhCETP (IC50:7.9±2.5 nM) 和 C13S CETP 突变型 (IC50:11.8±1.9 nM) 的活性。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1135 |
Vitamin D3
维生素D3,Cholecalciferol,Colecalciferol |
Endogenous Metabolite | Metabolism |
Vitamin D3 (Cholecalciferol) 是维生素 D 的一种天然存在形式,代谢激活后可以诱导细胞分化和癌细胞增殖。 | |||
T7970 |
7-Ethoxycoumarin
|
Others | Others |
7-Ethoxycoumarin 是细胞色素 P450(CYP) 的底物,现已被应用于多种 CYP 的功能表征。 | |||
TN5254 |
Wighteone
Erythrinin B,6-Isopentenylgenistein |
Antifungal | Microbiology/Virology |
Wighteone (Erythrinin B) 是一种从 Genista ephedroides 中提取出来的小分子化合物,具有潜在的抗真菌和抗癌活性,对 EGFR L858R/T790M 突变非小细胞肺癌具有抗肿瘤作用。。 | |||
TN1140 |
Onjisaponin B
|
AMPK; mTOR; Autophagy | Autophagy; Chromatin/Epigenetic; PI3K/Akt/mTOR signaling |
Onjisaponin B 是从远志中提取的一种天然产物,可通过 AMPK-mTOR 信号通路诱导自噬,提高 NGF 水平并加速突变型亨廷顿蛋白和 A53T α±-突触核蛋白的清除,可研究帕金森病和亨廷顿病。 | |||
T1717 |
alpha-Mangostin
α-倒捻子素,α-Mangostin,Mangostin |
Apoptosis; Virus Protease; Dehydrogenase; Reactive Oxygen Species; Antibacterial; Antifungal | Apoptosis; Immunology/Inflammation; Metabolism; Microbiology/Virology; NF-κB |
alpha-Mangostin (Mangostin) 是有多种生物活性的膳食呫吨酮。它是一种IDH1突变体的抑制剂,Ki 值为 2.85 μM。 | |||
TN5072 |
Strictosidine
|
Others | Others |
Strictosidine has DNA damaging activity in yeast RS 188N mutant, assessed as drug level required to produce 12 mm zone of inhibition. | |||
TN7544 |
(−)-Voacangarine
(−)-Voacristine,NSC 306219 |
Others | Others |
(–)-Voacangarine, an indole alkaloid isolated from V. africana, exhibits cytotoxicity towards various cell lines including HepG2, A375, MDA-MB-231, SH-SY5Y, and CT26 with IC50 values of 20 µg/ml. Additionally, it demonstrates cytostatic effects on wild-type S. cerevisiae and is cytotoxic to Δrad3-e5 and Δrad6-1 mutant strains of S. cerevisiae, which have defects in DNA strand break repair and the mutagenic repair pathway, respectively. | |||
T83133 |
Alternaphenol B2
|
Isocitrate Dehydrogenase (IDH) | Metabolism |
IDH1 Inhibitor 是一种化学化合物,其通过选择性抑制异柠檬酸脱氢酶1 (IDH1) 酶的活性来起作用。这种抑制剂对R132突变的IDH1酶特别有效,因此在某些类型的癌症治疗中具有潜在的应用价值。IDH1 Inhibitor能够阻断异常的代谢途径和纠正肿瘤细胞增殖的代谢异常。在药物研发和临床试验中,研究人员评估其对特定肿瘤生长的抑制效果及其安全性和耐受性。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-01464 |
IL-2 Superkine Protein, Human, Recombinant (L100F, R101D, L105V, I106V, I112F)
TCGF,Aldesleukin,T-Cell Growth Factor,IL-2,Interleukin-2,IL2 |
Human | HEK293 Cells |
Interleukin-2(IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system,belongs to the IL-2 family. It is a powerful immunoregulatory lymphokine produced by T-cells in response to antigenic or mitogenic stimulation. IL-2/IL-2R signaling is required for T-cell proliferation and other fundamental functions that are essential for the immune response. IL-2 stimulates growth and differentiation of B-cells, NK cells, lymphokine-activated killer cells, monocytes, macrophages... | |||
TMPY-00395 |
Insulin Protein, Human, Recombinant
IDDM1,MODY10,ILPR,IDDM2,IRDN,IDDM,insulin,INS |
Human | P. pastoris (Yeast) |
INS (Insulin) is a Protein Coding gene. This gene encodes insulin, a peptide hormone that plays a vital role in the regulation of carbohydrate and lipid metabolism. After removal of the precursor signal peptide, proinsulin is post-translationally cleaved into three peptides: the B chain and A chain peptides, which are covalently linked via two disulfide bonds to form insulin, and C-peptide. The binding of insulin to the insulin receptor (INSR) stimulates glucose uptake. Diseases associated with ... | |||
TMPJ-01011 |
FGF-9 Protein, Mouse, Recombinant (His)
heparin-binding growth factor-9,GAF,HBGF-9,Glia-activating f... |
Mouse | E. coli |
Fibroblast growth factor-9 (FGF-9) is an approximately 26 kDa secreted glycoprotein of the FGF family. Secreted mouse FGF-9 lacks the N-terminal 1-3 aa and shares >98% sequence identity with rat, human, equine, porcine and bovine FGF-9. FGF-9 plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation and cell migration. In the mouse embryo the location and timing of FGF-9 expression affects development of the skeleton, cerebellum, lungs, heart, v... | |||
TMPY-04552 |
AKT1 Protein, Human, Recombinant (His)
RAC-ALPHA,v-akt murine thymoma viral oncogene homolog 1,RAC,... |
Human | Baculovirus Insect Cells |
v-akt murine thymoma viral oncogene homolog 1 (AKT1), or protein kinase B-alpha (PKB-ALPHA) is a serine-threonine protein kinase, belonging to the Protein Kinase Superfamily. AKT1 is a major mediator of the responses to insulin, insulin-like growth factor 1 (IGF1), and glucose. AKT1 also plays a key role in the regulation of both muscle cell hypertrophy and atrophy. AKT1 activity is required for physiologic cardiac growth in response to IGF1 stimulation or exercise training. In contrast, AKT1 ac... | |||
TMPY-05099 |
GBA/glucocerebrosidase Protein, Human, Recombinant (His)
glucosidase, β, acid,GLUC,GCB,GBA1,glucosidase, beta, acid |
Human | HEK293 Cells |
Mutations in the GBA gene, encoding the lysosomal hydrolase glucocerebrosidase (GCase), are the most common known genetic risk factor for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). ASAH1 (acid ceramidase 1) and GBA2 (glucocerebrosidase 2) enzymes that mediate glucosylsphingosine production and metabolism are attractive therapeutic targets for treating mutant GBA-associated PD. | |||
TMPY-00483 |
Parvalbumin/PVALB Protein, Human, Recombinant (His)
parvalbumin,D22S749 |
Human | E. coli |
Parvalbumins (PVALBs) are particularly abundant in the fast-contracting muscles and correlate positively with muscle relaxation speed in amphibians and fishes. The loss of PVALB plays a role in the pathogenesis of thyroid tumors. The mutations in the PVALB gene are not involved in GS patients who harbour a single or no mutant SLC12A3 allele. | |||
TMPH-00721 |
YgiS Protein, E. coli, Recombinant (His & SUMO)
Probable deoxycholate-binding periplasmic protein YgiS,ygiS |
E. coli | E. coli |
Probably part of a deoxycholate transport system. Its expression in the presence of deoxycholate in a ygiS deletion mutant increases intracellular deoxycholate levels and decreases cell growth; higher expression in the presence of deoxycholate inhibits cell growth completely. Bile acid detergents such as deoxycholate are important for host defense against bacterial growth in the gall bladder and duodenum. | |||
TMPK-01508 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi)
TP53,Antigen NY-CO-13,P53,MHC,HLA-A,BCC7,LFS1,FLJ92943,TRP53 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01531 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein, Human, MHC (His & Avi)
Antigen NY-CO-13,MHC,FLJ92943,TRP53,HLA-A,BCC7,TP53,LFS1,P53 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01532 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein, Human, MHC (His & Avi)
Antigen NY-CO-13,BCC7,FLJ92943,HLA-A,LFS1,P53,TP53,TRP53,MHC |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01509 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein, Human, MHC (His & Avi)
TRP53,HLA-A,TP53,LFS1,P53,MHC,FLJ92943,BCC7,Antigen NY-CO-13 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01437 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
FLJ92943,HLA-A,TP53,Antigen NY-CO-13,TRP53,MHC,BCC7,P53,LFS1 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01538 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LFS1,Antigen NY-CO-13,HLA-A,BCC7,TP53,TRP53,FLJ92943,P53 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01442 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
HLA-A,P53,TP53,LFS1,MHC,BCC7,TRP53,FLJ92943,Antigen NY-CO-13 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-00113 |
Pentraxin 2/SAP Protein, Mouse, Recombinant (hFc)
APCS,MGC88159,SAP,Pentraxin 2,PTX2 |
Mouse | HEK293 Cells |
Pentraxin-2 (PTX-2), also known as serum amyloid P component (SAP/APCS), is a constitutive, antiinflammatory, innate immune plasma protein whose circulating level is decreased in chronic human fibrotic recombinant human PTX-2 (rhPTX-2) retards progression of chronic kidney disease in Col4a3 mutant mice with Alport syndrome, reducing blood markers of kidney failure, enhancing lifespan by 20%, and improving histological signs of disease. diseases. Pentraxin 2/SAP Protein, Mouse, Recombinant (hFc) ... | |||
TMPK-00692 |
EGFRVIII Protein, Human, Recombinant (His & Avi), Biotinylated
EC 2.7.10.1,PIG61,NISBD2,HER1,mENA,LEGFR,ErbB,EC 2.7.10,ERBB... |
Human | HEK293 Cells |
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand. EGFRVIII Protein, Human, Recombinant (His & Avi), Biotinylated is exp... | |||
TMPY-03465 |
Flagellin Protein, Listeria monocytogenes, Recombinant (His)
flaA |
Listeria monocytogenes | E. coli |
The role of flagella and motility in the attachment of the foodborne pathogen Listeria monocytogenes to various surfaces is mixed with some systems requiring flagella for an interaction and others needing only motility for cells to get to the surface. In nature this bacterium is a saprophyte and contaminated produce is an avenue for infection. Previous studies have documented the ability of this organism to attach to and colonize plant tissue. Motility mutants were generated in three wild ... | |||
TMPK-01552 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
TP53,TRP53,HLA-A,MHC,Antigen NY-CO-13,BCC7,LFS1,P53,FLJ92943 |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-00690 |
EGFRVIII Protein, Human, Recombinant (His & Avi), FITC-Labeled
LEGFR,ERBB1,EGFR,HER1,PIG61,NISBD2,EC 2.7.10,ERBB,EC 2.7.10.... |
Human | HEK293 Cells |
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand. EGFRVIII Protein, Human, Recombinant (His & Avi), FITC-Labeled is exp... | |||
TMPK-00691 |
EGFRVIII Protein, Human, Recombinant (His & Avi)
EGFR,ErbB,mENA,HER1,LEGFR,EC 2.7.10.1,PIG61,EC 2.7.10,ERBB1,... |
Human | HEK293 Cells |
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand. EGFRVIII Protein, Human, Recombinant (His & Avi) is expressed in HEK2... | |||
TMPK-00765 |
Pentraxin 2/SAP Protein, Human, Recombinant (hFc)
PTX2,SAP,Pentraxin 2,MGC88159,APCS |
Human | HEK293 Cells |
Pentraxin-2 (PTX-2), also known as serum amyloid P component (SAP/APCS), is a constitutive, antiinflammatory, innate immune plasma protein whose circulating level is decreased in chronic human fibrotic recombinant human PTX-2 (rhPTX-2) retards progression of chronic kidney disease in Col4a3 mutant mice with Alport syndrome, reducing blood markers of kidney failure, enhancing lifespan by 20%, and improving histological signs of disease. diseases. Pentraxin 2/SAP Protein, Human, Recombinant (hFc) ... | |||
TMPY-04152 |
RAB7A Protein, Rat, Recombinant (His)
RAB7A, member RAS oncogene family,Rab7 |
Rat | E. coli |
RAB7A is a ubiquitous small GTPase, which controls transport to late endocytic compartments. Silencing or overexpression of wild type RAB7A changed the soluble/insoluble rate of peripherin indicating that RAB7A is important for peripherin organization and function. Besides, disease-causing RAB7A mutant proteins bind more strongly to peripherin and their expression causes a significant increase in the amount of soluble peripherin. The altered interaction between disease-causing RAB7A mutants and ... | |||
TMPY-02426 |
UBE2D1 Protein, Human, Recombinant (His)
UBC4/5,E2(17)KB1,ubiquitin-conjugating enzyme E2D 1,UBCH5,UB... |
Human | E. coli |
Ubiquitin-conjugating enzyme E2 D1 (UBE2D1), a member of human E2 ubiquitin-conjugating enzymes, is closely related to SFT, which is short for stimulator of iron (Fe) transport. In other words, UbcH5A is significantly up-regulated in the liver of iron-overloaded patients with hereditary hemochromatosis, as previously published for SFT. Moreover, a complex of UBE2D1 is critical in maintaining KRAS protein stability and propose that targeting such complex may be a unique strategy to degrade mutant... | |||
TMPK-00689 |
EGFRVIII Protein, Human, Recombinant (His & Avi), PE-Labeled
EC 2.7.10.1,EC 2.7.10,ERBB1,EGFR,mENA,NISBD2,HER1,ErbB,PIG61... |
Human | HEK293 Cells |
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand. EGFRVIII Protein, Human, Recombinant (His & Avi), PE-Labeled is expre... | |||
TMPJ-00604 |
KIR2DL4 Protein, Human, Recombinant (His)
CD158 Antigen-Like Family Member D,KIR2DL4,MHC Class I NK Ce... |
Human | HEK293 Cells |
Killer cell immunoglobulin-like receptor 2DL4(KIR2DL4) is a Single-pass type I membrane protein and contains 2 Ig-like C2-type (immunoglobulin-like) domains.It belongs to the immunoglobulin superfamily. KIR2DL4 is expressed in all NK cells and some T cells. KIR2DL4 activates the cytotoxicity of NK cells, despite the presence of an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic tail. The ITIM was not necessary for activation of lysis by KIR2DL4. The activation signal of ... | |||
TMPJ-00869 |
GLB1 Protein, Human, Recombinant (His)
Lactase,Acid Beta-Galactosidase,Elastin Receptor 1,GLB1,Acid... |
Human | HEK293 Cells |
β Galactosidase is a lysosomal β Galactosidase that hydrolyzes the terminal β Galactose from Ganglioside and Keratan sulfate. In lysosome, the mature β Galactosidase protein associates with Cathepsin A and Neuraminidase 1 to form the lysosomal multienzyme complex . An alternative splicing at the RNA level of β Galactosidase results a catalytically inactive β Galactosidase that plays an important role in vascular development. Defects of β-galactosidase (GLB1) are the cause of diseases like GM1-ga... | |||
TMPY-03991 |
DBI Protein, Human, Recombinant (His)
diazepam binding inhibitor (GABA receptor modulator, acyl-Co... |
Human | E. coli |
The diazepam binding inhibitor (DBI), alternatively known as the acyl-CoA binding protein (ACBP), is involved in multiple biological actions. The polypeptide binds to the peripheral, or mitochondrial, benzodiazepine receptor and facilitates transport of cholesterol to the inner membrane to stimulate steroid synthesis. Through this action, DBI indirectly modulates gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission. DBI can be postulated as a candidate gene for psychiatric phenot... | |||
TMPY-02961 |
PANP/C12orf53 Protein, Human, Recombinant (hFc)
C12orf53,UNQ828/PRO1755,PILR α associated neural protein,PAN... |
Human | HEK293 Cells |
C12orf53 is mainly expressed in adult brain and cerebellum. It also can be detected in fetal brain and virtually no expression in spleen, heart, kidney, liver and dorsal ganglion relative to brain. C12orf53 acts as a ligand for PILRA in neural tissues, where it may be involved in immune regulation. Chromosome 12 encodes over 1,100 genes within 132 million bases. A number of skeletal deformities are linked to chromosome 12 including hypochondrogenesis, achondrogenesis and Kniest dysplasia. Noonan... | |||
TMPY-01479 |
SPG3A Protein, Human, Recombinant (GST)
HSN1D,atlastin GTPase 1,FSP1,atlastin1,GBP3,SPG3,SPG3A,AD-FS... |
Human | Baculovirus Insect Cells |
Atlastin-1, also known as Spastic paraplegia 3 protein A, Guanine nucleotide-binding protein 3, GTP-binding protein 3, GBP3, ATL1 and SPG3A, is a multi-pass membrane protein which belongs to theGBP family and atlastin subfamily. ATL1 / SPG3A is expressed predominantly in the adult and fetal central nervous system. Expression of ATL1 / SPG3A in adult brain is at least 5-fold higher than in other tissues. ATL1 / SPG3A is detected predominantly in pyramidal neurons in the cerebral cortex and... | |||
TMPY-03442 |
MOB4A/MOB1B Protein, Human, Recombinant (GST)
MOB kinase activator 1B,MOBKL1A,MATS2,MOB4A |
Human | E. coli |
MST1 and MST2 are the mammalian Ste2-related protein kinases most closely related to Drosophila Hippo, a major regulator of cell proliferation and survival during development. Overexpression of MST1 or MST2 in mammalian cells is proapoptotic. MST1 and MST2 activity increase during mitosis, especially in nocodazole-arrested mitotic cells, where these kinases exhibit an increase in both abundance and activation. MST1 and MST2 also can be activated nonphysiologically by okadaic acid or H2O2. The MO... | |||
TMPY-01187 |
Rac1 Protein, Human, Recombinant (GST)
Rac-1,p21-Rac1,MIG5,ras-related C3 botulinum toxin substrate... |
Human | Baculovirus Insect Cells |
RAC1 is a GTPase that belongs to the RAS superfamily of small GTP-binding proteins. Members of this superfamily appear to regulate a diverse array of cellular events, including the control of cell growth, cytoskeletal reorganization, and the activation of protein kinases. Two transcript variants encoding different isoforms have been found for RAC1 gene. RAC1 is a plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, bind... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TMIH-0549 |
Tafamidis-d3
|
||
Tafamidis-d3 是 Tafamidis 的氘代化合物。Tafamidis 的 CAS 号为 594839-88-0。Tafamidis 是选择性的transthyretin (TTR)稳定剂,对野生型 WT-TTR 、突变型同源四聚体 V30M-TTR、V122I-TTR 的活性相当,它们的EC50值为2.7-3.2 μM。它对淀粉样蛋白的生成具有抑制作用。 | |||
T71211 |
Rizatriptan-d6 benzoate salt
|
||
Rizatriptan-d6 is intended for use as an internal standard for the quantification of rizatriptan by GC- or LC-MS. Rizatriptan is an agonist of the serotonin receptor subtypes 5-HT1B and 5-HT1D. It is selective for 5-HT1B and 5-HT1D receptors over 5-HT1A receptors. Rizatriptan induces vasoconstriction in isolated human middle meningeal arteries. In vivo, rizatriptan reduces head grooming, the number of oculotemporal strokes, eye blinking, and one-eye closures in a Cacna1a mutant transgenic mou... |